Abstract 1097P
Background
Achieving a complete response (CR) with ICI is associated with a long term survival in advanced melanoma pts. The long term outcome of pts for which the CR is obtained by a local procedure (LP) such as surgery, radiotherapy or interventional radiology following ICI is not known. We report here long term relapse-free survival (RFS) and overall survival (OS) data of a cohort of pts in this situation.
Methods
RFS and OS of melanoma pts with a CR obtained by ICI + LP were estimated from the time of LP to progression or death using the Kaplan-Meier method. Pts with no viable cells in the resected metastases were excluded.
Results
40 pts (57.5% males) with a mean age of 52.4 years achieved a CR after receiving ICI combined by an additional LP on 1 to 3 stable or progressing metastatic sites including lymph nodes, skin, lung, liver and brain. Most pts had received previous treatment lines (mean: 2.9). 23 (57.5%) pts were in progression according to RECIST 1.1 before the LP, 5 (12.5%) pts were in partial response, and 1(2.5%) pt in stable disease. 4 (10%) pts had a dissociated response and for 7 (17.5%) pts the response was not evaluable. Median duration between ICI onset and LP was 8.9 months [3.9–16.4]. After a median duration of follow-up of 5.4 years from LP, the median duration of response was not reached, 5 years RFS and OS rates were 58.65% [44.52–77.27] and 88.57% [78.63–99.76] respectively. Median RFS and OS were not reached. Relapses occurred in 14 (35%) pts, most often on a site different from that treated by the LP.
Conclusions
This real life study shows that long term RFS and OS can be achieved when ICI is given before a LP at oligometastatic sites in spite of tumor progression following ICI and suggests that neoadjuvant ICI should be evaluated in stage IV pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Caroline Robert.
Funding
Has not received any funding.
Disclosure
E. Routier: Financial Interests, Personal and Institutional, Other, Compensation: BMS, Novartis, Pierre Fabre; Financial Interests, Personal and Institutional, Invited Speaker: BMS, Novartis, Pierre Fabre. C. Boutros: Financial Interests, Personal and Institutional, Advisory Board: BMS; Financial Interests, Personal and Institutional, Invited Speaker: MSD; Financial Interests, Personal and Institutional, Other, Meeting fees: Pierre Fabre. C. Robert: Financial Interests, Personal and Institutional, Advisory Role: BMS, Novartis, Pierre Fabre, MSD, Roche, Sanofi, AstraZeneca, Merck; Financial Interests, Personal, Other, Cofounder of Ribonexus. All other authors have declared no conflicts of interest.
Resources from the same session
899P - Impact of COVID-19 pandemic on treatment and survival in head and neck squamous cell carcinoma (HNSCC) patients (IMPACCT Study)
Presenter: Berta Vilar Anglada
Session: Poster session 12
900P - COVID-19 in patients with head and neck cancers (HERODOTUS): An international, registry-based, cohort study
Presenter: Amanda Psyrri
Session: Poster session 12
901P - Gut microbiome metagenomics and toxicity outcomes from chemoradiation therapy in head and neck squamous cell carcinoma
Presenter: Antoine Desilets
Session: Poster session 12
902P - Cisplatin-induced ototoxicity in head and neck cancer: The patterns and prediction
Presenter: Chiaki Suzuki
Session: Poster session 12
903P - AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes
Presenter: Renata Ferrarotto
Session: Poster session 12
904P - Retrospective analysis of adjuvant systemic anti-hormonal therapy for resected androgen receptor-positive (AR+) salivary duct carcinoma (SDC)
Presenter: Jetty Weijers
Session: Poster session 12
905P - Hot topics in salivary gland carcinomas treatment: An EORTC young investigator and early career investigator survey
Presenter: Luigi Lorini
Session: Poster session 12
906P - Multi-parameter flow cytometry analysis of circulating immune cell populations in recurrent/metastatic adenoid cystic carcinoma
Presenter: Samuel Rack
Session: Poster session 12
907P - Radiosensitivity signature in adenoid cystic carcinoma (ACC) of salivary glands origin is associated with ACC type II
Presenter: Laura Locati
Session: Poster session 12
908P - Efficacy of NOTCH inhibitors (Ni) relative to prior systemic therapy or observation in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC)
Presenter: Camilla Hoff
Session: Poster session 12